Dopamine-Secreting Neurocytes

Overview

Specialized dopaminergic neural cells differentiated from UCT-WJ-MSCs, engineered to restore dopamine synthesis and secretion in neurodegenerative and neuropsychiatric conditions

Related: Stem Cells Overview • Neurocyte Exosomes

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

Clinical Overview

Dopamine-Secreting Neurocytes represent one of the most targeted products in regenerative neurology. Parkinson's disease afflicts over 10 million people worldwide^[1] and is defined at its core by progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNc); by the time motor symptoms manifest, approximately 60–80% of SNc dopaminergic neurons have already been lost.^[2] Current pharmacologic management (levodopa, dopamine agonists, MAO-B inhibitors) addresses the symptom but not the neurodegeneration, and produces diminishing returns and increasingly intolerable side effects (dyskinesias, on-off phenomena, psychosis) as the disease advances.^[3]

AB Dopamine-Secreting Neurocytes are specifically differentiated to recapitulate the function of substantia nigra dopaminergic neurons. They express the rate-limiting enzyme of dopamine synthesis, tyrosine hydroxylase (TH), along with the dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2), enabling authentic dopamine packaging and regulated secretion. Critically, these cells also secrete neurotrophic factors (GDNF, BDNF, NGF) that protect surviving host dopaminergic neurons — providing both cell replacement and neuroprotection simultaneously, a dual mechanism that distinguishes cell therapy from all pharmacologic alternatives. Their immune-privileged status enables allogeneic delivery without immunosuppressants; glucose-based, DMSO-free cryopreservation preserves TH enzymatic function and dopamine synthesis capacity across freeze-thaw cycles, avoiding the documented CNS toxicity risk (seizures, encephalopathy) of DMSO cryomedia in cell-infusion settings.

Mechanism of Action

1. Dopamine Synthesis — The Full Enzymatic Pathway: the pathway is intact and validated through all steps — tyrosine is converted to L-DOPA by tyrosine hydroxylase (TH, the rate-limiting, biopterin-dependent step), decarboxylated to dopamine by AADC/DDC, packaged into secretory vesicles by VMAT2 (protecting it from cytoplasmic oxidation), and released via calcium-evoked, physiologically regulated exocytosis onto D1/D5 and D2/D3/D4 striatal receptors. This regulated release is intended as an alternative to exogenous levodopa, whose non-physiologic pulsatile dopamine surges are established as responsible for dyskinesia development.^{[4] [5]} Transplanted cells are shown by PET imaging in human trials to survive and release dopamine;^[6] the degree to which release is tonic and physiologically regulated — rather than contributing to graft-induced dyskinesia, as documented with grafts containing serotonergic contamination^[7] — depends on graft purity, which the TH+ dopaminergic-only specification is intended to ensure.

2. Synaptic Integration into Nigrostriatal Circuitry: transplanted dopaminergic neurocytes extend TH+ axonal projections into the host striatum, forming synaptic-like contacts with striatal medium spiny neurons. In 6-OHDA Parkinson's rat models, TH+ fiber reinnervation of the dorsal striatum has been detected as early as 6 weeks post-transplantation by immunohistochemistry, correlating with improvement in rotational asymmetry testing.^[8]

3. Neuroprotection via GDNF/BDNF Secretion: GDNF/Ret/GFRα1 signaling is the most potent known survival factor for SNc dopaminergic neurons, activating PI3K/Akt (survival) and MAPK/ERK (axonal growth) — GDNF delivery to the putamen produced dramatic behavioral recovery and TH+ fiber restoration in MPTP primate PD models, the strongest neuroprotection evidence in any PD preclinical model.^[9] BDNF/TrkB suppresses proapoptotic markers in dopaminergic neurons and activates CREB-mediated survival gene transcription;^[10] NGF/TrkA supports cholinergic neurons in the basal forebrain, relevant to cognitive and autonomic symptoms in PD dementia.^[11]

4. α-Synuclein Aggregate Clearance: α-synuclein — the pathological protein that forms Lewy bodies in PD — is a well-established and actively pursued PD therapeutic target overall,^[12] though its modulation via cell therapy specifically is a less directly evidenced mechanism. AB Dopamine Neurocyte exosomes carry molecular chaperones and ubiquitin-proteasome pathway components that facilitate clearance of misfolded α-synuclein in recipient cells; in an MPTP mouse PD model, MSC-derived exosomes significantly prevented α-synuclein aggregation in the midbrain and preserved TH-positive dopaminergic neuron density in the striatum and substantia nigra relative to untreated MPTP mice — a directly applicable mechanism.^[13]

5. Neuroinflammation Control: like their MSC parent, AB Dopamine Neurocytes modulate microglial activation through IL-10 and IDO secretion. Neuroinflammation in the SNc is now understood to be an active accelerator — not merely a consequence — of dopaminergic neuron loss in PD: activated microglia produce reactive oxygen species, TNF-α, and IL-1β that directly kill dopaminergic neurons, a mechanism AB cell-mediated microglial M2 polarization directly combats.

Key Biomarkers & Molecular Cargo

Potential Applications

• Parkinson's Disease — dopaminergic neuron replacement, motor circuit restoration, GDNF neuroprotection
• Parkinson's-Plus Syndromes (MSA, PSP, DLB) — dopaminergic support
• Drug-Induced Parkinsonism — dopaminergic supplementation during antipsychotic-induced nigrostriatal blockade
• Dystonia — dopamine pathway normalization, basal ganglia circuit repair
• Tourette Syndrome — dopaminergic/serotonergic balance modulation
• Treatment-Resistant Depression — dopamine reward circuit restoration (combined with serotonergic approaches)
• Bipolar Disorder — dopamine dysregulation modulation
• ADHD — prefrontal cortex dopamine enhancement, executive function support
• Schizophrenia (Negative Symptoms) — mesocortical D1-mediated cognitive improvement, distinct from mesolimbic hyperdopaminergia
• Motor Control Disorders / Restless Leg Syndrome — central dopaminergic tone restoration
• Dopamine Deficiency Syndromes — metabolic dopaminergic insufficiencies

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical & Preclinical Evidence

MSC-derived exosomes significantly prevented α-synuclein aggregation in the midbrain and preserved TH-positive dopaminergic neuron density in the striatum and substantia nigra relative to untreated mice, in an MPTP mouse PD model, via Nox4/ROS/Nrf2 anti-oxidant signaling.^[13]

Preclinical evidence in 6-OHDA rat and MPTP primate PD models — the preclinical standard and gold-standard models, respectively — reports motor improvement, TH+ fiber reinnervation of the striatum, and dopamine level normalization following dopaminergic cell transplantation; this specific preclinical evidence base is not yet tied to a single verifiable published source in Akira's current reference set and should be treated as directionally supportive rather than quantitatively definitive. Early-phase iPSC-derived dopaminergic neuron trials (n=12–20 across trials) report safe intracerebral delivery with DaT-scan signals of dopaminergic reinnervation at 12 months and motor improvement in a subset of patients, establishing a safety precedent for this cell class, though this too awaits a single citable source in Akira's reference set.